(Q39851910)

15 September 2017

title

Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment (English)

1 reference

15 September 2017

1 reference

1 reference

angiogenesis inhibitor

1 reference

1 reference

1 reference

K Guse

1

1 reference

15 September 2017

I Diaconu

2

1 reference

15 September 2017

M Rajecki

3

1 reference

15 September 2017

M Sloniecka

4

1 reference

15 September 2017

T Hakkarainen

5

1 reference

15 September 2017

A Ristimäki

6

1 reference

15 September 2017

A Kanerva

7

1 reference

15 September 2017

S Pesonen

8

1 reference

15 September 2017

A Hemminki

9

1 reference

15 September 2017

publication date

14 May 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

16

1 reference

15 September 2017

issue

8

1 reference

15 September 2017

page(s)

1009-1020

1 reference

Global cancer statistics, 2002

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Adenoviruses for treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Virotherapy as an approach against cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Gene therapy progress and prospects cancer: oncolytic viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Cancer selective adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Clinical trials with oncolytic adenovirus in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Role of vascular endothelial growth factor in the regulation of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Different roles of ERK and p38 MAP kinases during tube formation from endothelial cells cultured in 3-dimensional collagen matrices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

High interstitial fluid pressure - an obstacle in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Vascular endothelial growth factor trap in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Characterization of physiologically regulated vectors for the treatment of ischemic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

HIF1A signaling selectively supports proliferation of breast cancer in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

7 January 2021

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

7 January 2021

Vascular endothelial growth factor expression is increased in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

7 January 2021

Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

7 January 2021

Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor 1 by low oxygen tension

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.56

7 January 2021

Immunotherapy for advanced renal cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

DOI

10.1038/GT.2009.56

1 reference

15 September 2017

1 reference